Inpatient diabetes control: Rationale

Diabetes Care

Volumn 27, Issue 8, 2004, Pages 2074-2080

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DICHLOROACETIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; ETOMOXIR; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; PIOGLITAZONE; POTASSIUM; PROGESTERONE; RANOLAZINE; ROSIGLITAZONE; STATINE DERIVATIVE; TRANDOLAPRIL;

ACUTE HEART INFARCTION; ANGIOPLASTY; ATHEROSCLEROTIC PLAQUE; BYPASS SURGERY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CRITICAL ILLNESS; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; INSULIN TREATMENT; INTENSIVE CARE UNIT; LENGTH OF STAY; META ANALYSIS; METABOLIC REGULATION; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PREGNANCY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; WOUND INFECTION;

BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; INPATIENTS; LENGTH OF STAY; PREGNANCY; PREGNANCY IN DIABETICS;

EID: 3342988065     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.8.2074     Document Type: Review

References (45)

1. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators: Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 335:217-225, 1996
2. Hlatky MA, Rogers WJ, Johnstone I, Boothroyd D, Brooks MM, Pitt B, Reeder G, Ryan T, Smith H, Whitlow P, Wiens R, Mark DB: Medical care costs and quality of life after randomization to coronary angioplasty or coronary bypass surgery: Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 336:92-99, 1997
3. Frye RL: Optimal care of patients with type 2 diabetes mellitus and coronary artery disease. Am J Med 115 (Suppl. 8A): 93S-98S, 2003
4. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314:1512-1515, 1997
5. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) registry. Circulation 102:1014-1019, 2000
6. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359:2140-2144, 2002
7. Oswald GA, Smith CC, Betteridge DJ, Yudkin JS: Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br Med J 293:917-922, 1986
8. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
9. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW, Flaker GC, Braunwald E, Pfeffer MA; CARE Study: Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study. J Am Coll Cardiol 42:1446-1453, 2003
10. Heeschen C, Dimmeler S, Fichtlscherer S, Hamm CW, Berger J, Simoons ML, Zeiher AM, the CAPTURE Investigators: Prognostic value of placental growth factor in patients with acute chest pain. JAMA 291: 435-441, 2004
11. Mock MB, Ringqvist I, Fisher LD, Davis KB, Chaitman BR, Kouchoukos NT, Kaiser GC, Alderman E, Ryan TJ, Russell RO Jr, Mullin S, Fray D, Killip T 3rd: Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 66:562-568, 1982
12. Cipollone F, Iezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A: The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108:1070-1077, 2003
13. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, Crandall J, Badimon JJ: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107: 973-977, 2003
14. Iwasaka T, Takahashi N, Nakamura S, Sugiura T, Tarumi N, Kimura Y, Okubo N, Taniguchi H, Matsui Y, Inada M: Residual left ventricular pump function after acute myocardial infarction in NIDDM patients. Diabetes Care 15:1522-1526, 1992
15. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P: Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction: Trace Study Group. J Am Coll Cardiol 34:83-89, 1999
16. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL, the ICONS Investigators: Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 40:1748-1754, 2002
17. Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, Boura J, O'Neill W, Grines CL, the Primary Angioplasty in Myocardial Infarction (PAMI) Investigators: Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 42: 1739-1746, 2003
18. Wambolt RB, Lopaschuk GD, Brownsey RW, Allard MF: Dichloroacetate improves postischemic function of hypertrophied rat hearts. J Am Coll Cardiol 36: 1378-1385, 2000
19. Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96:1152-1156, 1997
20. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G: Metabolic modulation of acute myocardial infarction: the ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 98:2227-2234, 1998
21. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86:3257-3265, 2001
22. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubota N, Saito T, Masuda Y, Kadowaki T, Komuro I: Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240-1246, 2002
23. Shiomi T, Tsutsui H, Hayashidani S, Suematsu N, Ikeuchi M, Wen J, Ishibashi M, Kubota T, Egashira K, Takeshita A: Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106:3126-3132, 2002
24. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R, the American Heart Association, the American Diabetes Association: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948, 2003
25. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A: Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 67:352-360, 1999
26. Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A: Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 63:356-361, 1997
27. Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A: Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg 125:1007-1021, 2003
28. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, the Women's Health Initiative Investigators: Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523-534, 2003
29. Riddle MC, Hart J: Hyperglycemia, recognized and unrecognized, as a risk factor for stroke and transient ischemic attacks. Stroke 13:356-359, 1982
30. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab 87:978-982, 2002
31. Levetan CS, Passaro M, Jablonski K, Kass M, Ratner RE: Unrecognized diabetes among hospitalized patients. Diabetes Care 21:246-249, 1998
32. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC: Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 32:2426-2432, 2001
33. Weir CJ, Murray GD, Dyker AG, Lees KR: Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ 314:1303-1306, 1997
34. Pulsinelli W, Waldman S, Sigsbee B, Rawlinson D, Scherer P, Plum F: Experimental hyperglycemia and diabetes mellitus worsen stroke outcome. Trans Am Neurol Assoc 105:21-24, 1980
35. Baird TA, Parsons MW, Phanh T, Butcher KS, Desmond PM, Tress BM, Colman PG, Chambers BR, Davis SM: Persistent post-stroke hyperglycemia is independently associated with infarct expansion and worse clinical outcome. Stroke 34:2208-2214, 2003
36. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS: Stroke in patients with diabetes: the Copenhagen Stroke Study. Stroke 25:1977-1984, 1994
37. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H: Effects of insulin treatment on cause-specific one-year mortality and morbidity in diabetic patients with acute myocardial infarction: DIGAMI Study Group: Diabetes Insulin-Glucose in Acute Myocardial Infarction. Eur Heart J 17:1337-1344, 1996
38. Pittet D, Tarara D, Wenzel RP: Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 271: 1598-601, 1994
39. Nielson CP, Hindson DA: Inhibition of polymorphonuclear leukocyte respiratory burst by elevated glucose concentrations in vitro. Diabetes 38:1031-1035, 1989
40. Bagdade JD, Root RK, Bulger RJ: Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 23:9-15, 1974
41. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H: Infection and diabetes: the case for glucose control. Am J Med 72:439-450, 1982
42. Trick WE, Scheckler WE, Tokars JI, Jones KC, Smith EM, Reppen ML, Jarvis WR: Risk factors for radial artery harvest site infection following coronary artery by-pass graft surgery. Clin Infect Dis 30:270-275, 2000
43. Mesotten D, Delhanty PJ, Vanderhoydonc F, Hardman KV, Weekers F, Baxter RC, Van Den Berghe G: Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Clin Endocrinol Metab 87:5516-5523, 2002
44. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345: 1359-1367, 2001
45. Van den Berghe G, Wouters PJ, Bouillon R, Weekers F, Verwaest C, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P: Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycemic control. Crit Care Med 31:359-366, 2003